이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Diaceutics 대차 대조표 상태

재무 상태 기준 확인 6/6

Diaceutics 의 총 주주 지분은 £40.8M 이고 총 부채는 £0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 £46.3M 및 £5.6M 입니다.

주요 정보

부채 비율

UK£0

부채

이자 보상 비율	n/a
현금	UK£16.75m
주식	UK£38.74m
총 부채	UK£6.69m
총 자산	UK£45.43m

최근 재무 상태 업데이트

업데이트 없음

Recent updates

Diaceutics PLC (LON:DXRX) Stock Rockets 29% But Many Are Still Ignoring The Company

May 30

Diaceutics PLC's (LON:DXRX) Subdued P/S Might Signal An Opportunity

Jan 31

Industry Analysts Just Made A Notable Upgrade To Their Diaceutics PLC (LON:DXRX) Revenue Forecasts

Jan 28

Estimating The Intrinsic Value Of Diaceutics PLC (LON:DXRX)

Jul 24

Would Shareholders Who Purchased Diaceutics' (LON:DXRX) Stock Year Be Happy With The Share price Today?

Feb 04

Here's Why We Don't Think Diaceutics's (LON:DXRX) Statutory Earnings Reflect Its Underlying Earnings Potential

Dec 31

Do Insiders Own Lots Of Shares In Diaceutics PLC (LON:DXRX)?

Nov 27

재무 상태 분석

단기부채: DXRX 의 단기 자산 ( £28.0M )이 단기 부채( £4.4M ).

장기 부채: DXRX 의 단기 자산( £28.0M )이 장기 부채( £1.2M ).

부채 대 자본 내역 및 분석

부채 수준: DXRX 부채가 없습니다.

부채 감소: DXRX 는) 부채 대 자기자본 비율이 142.5% 였던 5년 전과 비교하여 부채가 없습니다.

부채 범위: DXRX 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: DXRX 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

Diaceutics 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Recent updates

Consensus EPS estimates upgraded to UK£0.016 loss

First half 2024 earnings: EPS and revenues exceed analyst expectations

Diaceutics PLC to Report Q2, 2024 Results on Sep 17, 2024

Diaceutics PLC Launches Enhanced Rare-Disease Offering

Diaceutics PLC Announces Launch of PMx

Diaceutics plc Announces Board Changes

Now 21% overvalued after recent price rise

Consensus EPS estimates fall by 12%

Price target increased by 8.1% to UK£1.72

Diaceutics PLC (LON:DXRX) Stock Rockets 29% But Many Are Still Ignoring The Company

Independent Non-Executive Director recently bought UK£51k worth of stock

Full year 2023 earnings: Revenues in line with analyst expectations

Diaceutics PLC Launches Significant Upgrade to Its DXRX Platform

New minor risk - Market cap size

Diaceutics PLC's (LON:DXRX) Subdued P/S Might Signal An Opportunity

Diaceutics PLC, Annual General Meeting, Jun 24, 2024

New minor risk - Market cap size

Less than half of directors are independent

Consensus EPS estimates upgraded to UK£0.017 loss

First half 2023 earnings: EPS exceeds analyst expectations

New minor risk - Profit margin trend

Diaceutics Announces Executive Changes

Diaceutics PLC Announces Executive Changes, Effective 1 October 2023

Diaceutics plc Launches Daily Alerts for Dxrx Platform

Diaceutics PLC to Report First Half, 2023 Results on Sep 26, 2023

Full year 2022 earnings released: EPS: UK£0.009 (vs UK£0.007 in FY 2021)

Industry Analysts Just Made A Notable Upgrade To Their Diaceutics PLC (LON:DXRX) Revenue Forecasts

Diaceutics PLC Announces Release of Study into Inefficiencies Within Personalised Medicine and Its Impact on Cancer Patients

First half 2022 earnings released: UK£0.009 loss per share (vs UK£0.004 loss in 1H 2021)

Diaceutics PLC to Report First Half, 2022 Results on Sep 27, 2022

Diaceutics PLC Announces New AI and ML Capabilities Enhance DXRX Platform

No independent directors

Executive Officer recently sold UK£198k worth of stock

Diaceutics PLC Announces Test Signal Launch and Contract Wins

First half 2021 earnings released: UK£0.004 loss per share (vs UK£0.015 profit in 1H 2020)

Diaceutics PLC Provides Earnings Guidance for the Year 2021

Estimating The Intrinsic Value Of Diaceutics PLC (LON:DXRX)

CFO & Executive Director recently sold UK£246k worth of stock

Full year 2020 earnings released

New 90-day low: UK£1.12

Diaceutics PLC Appoints Nikita Lynn as Vice President of Finance

Would Shareholders Who Purchased Diaceutics' (LON:DXRX) Stock Year Be Happy With The Share price Today?

Diaceutics PLC to Report Fiscal Year 2020 Results on Mar 15, 2021

New 90-day high: UK£1.42

Here's Why We Don't Think Diaceutics's (LON:DXRX) Statutory Earnings Reflect Its Underlying Earnings Potential

Investor sentiment improved over the past week

Diaceutics PLC Announces the Resignation of Julie Goonewardene as Non-Executive Chair, with Effect from December 31, 2020

Diaceutics and Alva10 Partner to Deliver Value-Based Test Reimbursement Model for US Payers, Pharma and Testing Providers Via Dxrx Platform

Do Insiders Own Lots Of Shares In Diaceutics PLC (LON:DXRX)?

Diaceutics PLC Launches Diagnostic Network for Precision Medicine to Solve Global Cancer Testing Issues

Diaceutics PLC Partners with Global EQA Providers to Implement Best-In-Class Testing Standards

New 90-day low - UK£1.24

Diaceutics PLC announced that it has received £4 million in funding from SVB Silicon Valley Bank, Investment Arm

New 90-day high - UK£1.75

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기